Phase 2 study

Recruiting Phase 2

Sources: ClinicalTrials.gov Checked: 11 October 2026 Not medical advice

This trial at a glance

Status Recruiting
Phase Phase 2
Sponsor Melanoma Institute Australia
Registry number NCT06151236
Started 11 March 2024 Today 16 October 2026 Estimated completion 1 December 2026

Where this trial is running

Trial sites and the status recorded for each
SiteCityState or countryStatus at this site
Melanoma Institute Australia Wollstonecraft NSW Recruiting

voxsanity.com.au · trial sites from public registries · registry record synced 11 October 2026 · not medical advice

Who can join

Age 18 Years and over
Sex Anyone, regardless of sex
Healthy volunteers Not accepted
Enrolment target 20

The official eligibility criteria

Registry text, reproduced exactly. These are the words the trial's sponsor published on ClinicalTrials.gov. They have not been edited, shortened or rewritten, and they are written for researchers rather than for patients.

Inclusion Criteria:

1. Aged ≥ 18 years

2. Written consent

3. Histologically confirmed, resectable Merkel cell carcinoma with AJCC (8th ed) clinical or pathological stage I (≥ 10 mm), IIA, or IIB or III disease

4. In-transit metastases are permitted if they are completely resectable

5. Measurable disease according to RECIST 1.1 criteria

6. Previous radiotherapy permitted if there is RECIST-measurable progression of disease since the completion of radiotherapy

7. At least one of either, archival tissue from a primary or nodal MCC lesion (if applicable) for the current diagnosis and/or a newly obtained core biopsy of a lesion which has not been previously irradiated.

8. ECOG 0-1

9. Adequate organ function on blood pathology

10. Life expectancy \>12 months

11. Female patients to use effective contraception during study treatment and for 5 months after last dose.

Exclusion Criteria:

1. Clinical, radiographic or pathological evidence of distant metastases

2. Contraindication to nivolumab and / or relatlimab

3. Prior anti-PD-1, CTLA-4, PDL-1 or LAG 3 antibody exposure, or an agent directed to another stimulatory or co-inhibitory T-cell receptor for any disease or any chemotherapy or experimental local or systemic drug treatment

4. Active autoimmune disease or requirement for chronic steroid therapy other than hormone replacement therapy

5. A diagnosis of immunodeficiency or chronic steroid therapy \>10 mg OD prednisone or equivalent

6. Additional malignancy active within past 3 years; patients with chronic lymphocytic leukaemia can be included in this study.

7. Uncontrolled cardiovascular disease or history of myocarditis

8. Has had an allogenic tissue/solid organ transplant

9. Troponin T (TnT) or I (TnI) \>2 × institutional ULN

10. Has a history of (non-infectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis or current interstitial lung disease

11. Has an active infection requiring systemic therapy

12. Active Hepatitis B (defined as Hepatitis B surface antigen \[HBsAg\] reactive) or Hepatitis C virus (defined as HCV RNA \[qualitative\] is detected) infection.

13. Known HIV

14. Pregnant or breast feeding females

15. Concurrent medical or social conditions that may prevent the patient attending assessments or procedures per schedule

Dates on the record

Started 11 March 2024
Estimated completion 1 December 2026
Registry last updated 17 February 2026
Checked by Voxsanity 11 October 2026

Results, publications and the official record

Sources and dates

  • ClinicalTrials.gov – the record this page reformats
  • ClinicalTrials.gov processing date: 17 February 2026.
  • This page last checked by Voxsanity: 11 October 2026.

Voxsanity reformats data from public registries into this layout. It does not edit, interpret or add to what the registry published.

Not medical advice.

Individual trial records are refreshed on a rolling basis rather than all at once, so a record may be up to several weeks old. Each trial page and trial card shows the date its own record was last synced. Where a record has lagged, its status, sites and enrolment can differ from the current registry state in either direction, so check the registry link on the trial page before acting on them.

Letter for your doctor

A one-page summary of this trial to print or email to your GP. It carries the registry's own record of the trial and its eligibility criteria, and nothing Voxsanity has written about whether it suits you.